Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Cassava

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial.

Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops

Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing.

Investors Business Daily

Cassava Sciences Halts Alzheimer's Drug Trials After Phase 3 Results

Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company"))), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer's disease (AD) dementia, today announced

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pro AV Newsmakers: Sony Joins PSNI Global Alliance and Kramer's Big Week

Pro AV around the globe, new hires at ASG, and more from the week that was.

Drug Company's Libel Lawsuit Against Scientists Dismissed

From yesterday's decision by Judge Gregory Woods (S.D.N.Y.) in Cassava Sciences, Inc. v. Bredt: Cassava Sciences, Inc. ("Cassava") is a biotechnology company that is conducting clinical trials for an Alzheimer's drug called simufilam. Following the second phase of the simufilam clinical trials, multiple short sellers, most of them scientists, published…

Magistrate Judge/Zoologist Recommends Dismissal of Drug Company's Libel Claim Against Scientists

An excerpt from a long report and recommendation released Wednesday by Magistrate Judge Ona Wang (S.D.N.Y.) in Cassava Sciences, Inc. v. Bredt; for more details, read the whole opinion: At various dates in 2021, the Neuroscientist Defendants filed a Citizen Petition and sent publicly available letters to the Food and…

Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors

Cassava disappointed Tuesday with midstage results for its oral Alzheimer's treatment and SAVA stock plummeted by a double-digit percentage.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Cassava Plummets After Refuting New Claims Around Data Tampering Investigation

Cassava Plummets After Refuting New Claims Around Data Tampering Investigation

Cassava refuted reports Friday that it received a "termination letter" from officials surrounding an investigation — and SAVA stock fell.

Investors Business Daily

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow Rise

5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow Rise

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall

New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall

Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after

People

Barry Sonnenfeld

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Food and Drug Administration

Sony Electronics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play